BiotechTube
StromaBio

StromaBio

Stockholm, Sweden· Est.
stromabio.se
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.2M

Overview

StromaBio is a Swedish clinical-stage biotech leveraging over two decades of foundational research to develop allogeneic mesenchymal stromal cell (MSC) therapies. Its platform targets high-need areas in inflammatory and neurodegenerative diseases, specifically ARDS and Alzheimer's Disease. The company is built on a strong IP position and a decade of pre-clinical and clinical data, positioning it to advance two product candidates toward market authorization.

Acute Respiratory Distress SyndromeAlzheimer's Disease

Technology Platform

Allogeneic, bone marrow-derived mesenchymal stromal cell (MSC) platform leveraging immunomodulatory and anti-inflammatory properties for off-the-shelf cell therapy.

Funding History

1
Total raised:$1.2M
Seed$1.2M

Opportunities

The massive unmet need in Alzheimer's Disease and the critical care setting of ARDS represent multi-billion dollar market opportunities.
The allogeneic, 'off-the-shelf' nature of its MSC platform allows for scalable manufacturing and broad patient access, a significant commercial advantage.

Risk Factors

High clinical risk in proving efficacy in complex diseases like Alzheimer's, where many therapies have failed.
Significant regulatory and manufacturing hurdles for Advanced Therapy Medicinal Products (ATMPs), coupled with dependency on raising substantial capital to fund late-stage trials.

Competitive Landscape

The MSC therapy space is competitive, with numerous companies developing cells for inflammatory and autoimmune conditions. In ARDS, several biotechs are investigating cell therapies. In Alzheimer's, competition includes large pharma pursuing amyloid, tau, and other novel mechanisms, making StromaBio's cell-based approach a high-risk, high-reward differentiator.

More companies in Sweden →